Comparative Pharmacology
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus SERPANRAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus SERPANRAY.
FENOLDOPAM MESYLATE vs SERPANRAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.
None Documented
None Documented
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Terminal elimination half-life is approximately 62 hours following oral administration, allowing for once-daily dosing.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Primarily hepatic metabolism via CYP1A2 and CYP3A4, with 18% excreted unchanged in urine and 26% in feces as metabolites.
Category C
Category C
Antihypertensive
Antihypertensive